NCT07169643View on ClinicalTrials.gov

Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Liver Transplant; Complications

Interventions

DRUG

Darbepoetin (DP)

Darbepoetin (DP) 1.5 mcg/kg subcutaneously, monthly (The patients will receive medication monthly until the liver transplant is performed or if it has not yet been transplanted, a maximum of 3 doses)

All Listed Sponsors

lead

Fundacion Clinic per a la Recerca Biomédica

OTHER